-
Posted by
Two Blokes May 21, 2025 -
Filed in
Stock
-
4 views
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosimilars entered the market, stalling overall company growth. Dupixent continues strong growth with new approvals in COPD and CSU, keeping Regeneron profitable despite challenges.
